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ABSTRACT  
 
 
 
 
By now, the importance of inoculums development was well appreciated in 
bioprocessing. Inoculums development receives as much care and attention as the 
growth and product cycles. The status or “health” of the inoculums has a great deal 
to do with the success of the production cycle. In this project, inoculums 
development for the production of monoclonal antibody against Congenital Adrenal 
Hyperplasia (CAH) was studied. The scopes focused were the age of inoculums 
(passage number) and inoculums density at different growth phases. A hybridoma 
cell line (Hybridoma 192) was cultivated in batch mode with varying inoculums cell 
densities and growth phases using Dulbecco’s Modified Eagle Medium (DMEM). 
The maximum viable cell densities and the average specific MAb production rate (rp) 
were found to dependent on the inoculums cell density and the growth phases. 
Inoculums with low cell density at 5X10
4
cells/ml and early log phase (t=28h) have 
the highest average specific MAb production rate but a low maximum viable cell 
density. Varying inoculums cell densites and growth phases did not affect the 
specific growth rate, maximum MAb titer and net production of MAb. Since the 
inoculums density in the range of 5x10
4
 cells/ml to 5x10
5
 cells/ml and growth phase 
do not affect the net production of MAb, it is wise to use high initial inoculums cell 
density at 5x10
5
 cells/ml because the cell growth easily and faster compare low 
inoculums density. For the inoculums age, the average specific MAb production rate 
decreased when the passage number increased from PN (Passage Number) =9 to 
PN=30.Subculture exceeding critical passage number 9 was thus not recommended. 
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ABSTRAK 
 
 
 
 
Dalam projek ini, pembangunan inokulum untuk penghasilan monoklonal 
antibodi untuk menentang Congenital Adrenal Hyperplasia (CAH) telah dikaji. Skop 
yang difokuskan dalam pembangunan inokulum adalah umur inokulum, kepadatan 
sel inokulum dengan pelbagai fasa pertumbuhan hybridoma. Hybridoma dikulturkan 
dalam mode batch dengan pelbagai kepadatan sel inokulum dan fasa pertumbuhan 
dengan menggunakan Dulbecco’s Modified Eagle Medium (DMEM). Daripada 
pemerhatian, maksimum kepadatan sel yang hidup dan purata spesifik kadar 
penghasilan MAb adalah bergantung kepada kepadatan sel inokulum dan fasa 
pertumbuhan. Inokulum yang mempunyai kepadatan sel yang rendah pada 5X10
4 
sel/ml dan awal fasa pertumbuhan mempunyai nilai yang tinggi dalam purata spesifik 
kadar penghasilan MAb tetapi nilai yang rendah dalam maksimum sel yang hidup. 
Kadar spesifik pertumbuhan sel, maksimum MAb titer dan jumlah bersih 
penghasilan MAb tidak bergantung kepada pelbagai kepadatan sel inokulum dan fasa 
pertumbuhan. Walaupun kepadatan sel inokulum dan fasa pertumbuhan tidak 
mempengaruhi jumlah bersih penghasilan MAb tetapi ia adalah senang dan cepat jika 
mengunakan kepadatan sel inokulum yang tinggi seperti 5x10
5
 sel/ml. Dalam umur 
inokulum, purata spesifik kadar penghasilan Mab menurun apabila nombor passage 
bertambah dari PN=9 ke PN=30. Kritikal nombor passage adalah penting , apabila 
sel menjangkau nombor passage ini, sel perlu  dicairkan daripada sumber yang baru 
berbanding meneruskan sub-kultur di mana ia akan menpengaruhi penghasilan MAb.  
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CHAPTER 1 
 
 
 
 
INTRODUCTION 
 
 
 
 
1.1 Background of Study     
 
 
          Congenital Adrenal Hyperplasia (CAH) is a family inherited disorder seen in 
newborn which affecting the adrenal glands. The most common type, which occurs 
with a worldwide frequency of one per 15000 live births depending on the population, 
is associated with  deficiency of 21-hydroxylase (21-OHD) , which is inherited in 
severe or mild forms. The severe form, called Classical Congenital Adrenal 
Hyperplasia, is usually detected in the newborn period or in early childhood. The 
milder form, called Non-classical Congenital Adrenal Hyperplasia (NCAH), may 
cause symptoms at anytime from infancy through adulthood. NCAH is a much more 
common disorder than Classical CAH. Fortunately, CAH can be managed with 
medication and, with adequate care; affected individuals go on to live normal lives. 
 
 
        CAH is an autosomal recessive genetic disorder. It affects males and females in 
equal numbers. These particular groups of genes contain instructions the adrenal 
glands (located on top of the kidneys) need in order to produce an enzyme called 21-
hydroxylase. Without this enzyme, the adrenal glands are unable to produce cortisol, 
a hormone necessary for life. 
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        Cortisol is a steroid produced by the adrenal glands that our bodies need to deal 
with physical and emotional stress, and maintain adequate energy supply and blood 
sugar levels. The adrenal glands are controlled by the pituitary gland. The pituitary 
gland is a small pea-sized gland at the base of the brain. When the pituitary gland 
senses that there is not enough cortisol present in the bloodstream, it releases a 
hormone called ACTH (adrenocorticotropic hormone). ACTH stimulates the 
adrenals to produce more cortisol. However, those with CAH have insufficient 
amounts of the enzyme 21-hydroxylase, needed to convert a precursor molecule 
called 17-hydroxyprogesteron (17-OHP) into cortisol. As a result, the pituitary gland 
continues to sense the need for cortisol and pump out more ACTH. This leads to an 
overabundance of 17-OHP, which is converted in the adrenals into excess androgens 
(masculinizing steroid hormones). Lack of adequate cortisol also prevents the body 
from properly metabolizing sugar and responding to stress. The lack of this stress 
response can lead to an adrenal crisis. 
 
 
 The measurement of 17α-hydroxyprogesterone (17OHP) in serum or plasma 
is clinically useful for the diagnosis and management of congenital adrenal 
hyperplasia (CAH). The conventional method used for measuring 17OHP is 
conventionally based on competitive-binding radioimmunoassay or RIA (4, 5), 
using polyclonal antibody and usually require solvent extraction of samples. 
However, in the past decade clinics are learning more towards into using Enzyme 
immunoassays (EIA) for easier mass screening of steroids in patients‟ serum or 
plasma. EIA possesses several advantages over RIA. These include the avoidance of 
problems associated with the use of radioisotopes, the shorter incubation period and 
less work involved in the overall procedure. Additionally, immunoassay are now 
increasingly based on monoclonal antibodies (MAbs) instead of antisera (polyclonal 
antibodies). This is due to the fact that MAbs possess uniform characteristics, are 
well defined proteins and are readily available in unlimited supplies (H. Chong et al., 
2009). 
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1.2  Problem statement 
 
 
          Hybridoma technology which is established by Kohler and Milstein had been 
used and one of the cell line (Hybridoma 192) tested successfully to produce 
monoclonal antibody against Congenital Adrenal Hyperplasia (CAH) which is anti 
17-hydroxyprogesteron (17-OHP).The demand for the monoclonal antibody is high 
but the production or yield of monoclonal antibody by hybridoma is low. The scales-
up productions of monoclonal antibody are difficult and cause the cost of the 
process becomes very expensive. Besides that, during the cell culture, hybridoma 
cell have a high chance to contaminated and make the process more difficult. The 
main problem in the considerations is how to optimize the production of monoclonal 
antibody and second and how to ensure that the entire hybridoma cell is active and 
healthy. To solve this problem, inoculums development plays important roles in the 
initial stage to scale up the monoclonal antibody production.  
 
 
 
 
1.3  Objectives of Study 
 
 
         In the course of completing this project, there are few objectives to be fulfilled. 
There are 
1. To check the effect of inoculums age to the production of monoclonal 
antibody and cell growth. If it does affect, the maximum inoculums age that 
can be used in monoclonal antibody production will be determined. 
2. To check the effect of inoculums density and growth phase to the production 
of monoclonal antibody and cell growth. The suitable density that can be 
used in monoclonal antibody production will be determined. 
 
 
 
 
1.4 Scope of Study 
 
 
        Based on the objective, the main scope of this project is inoculums 
development in production of monoclonal antibody by hybridoma cell. The scope 
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including inoculums age, inoculums density and growth phase. For inoculums age, 
area that was study based on number of subcultures or passage number (30 times) of 
hybridoma cells on the production of monoclonal antibody and cell growth. For 
inoculums density and growth phases, the effect of different density(5x10
4
-5x10
5
 
cells/ml) together with different growth phases (early log phase, mid log phase and 
late log phase) of hybridoma cell on the production of monoclonal antibody and cell 
growth.  
          
 
 
 
1.5  Rational and Significance 
 
 
        Inoculums development is crucial to the initial stage of scale up the monoclonal 
antibody production. Through inoculums development, we can increase the quality 
of inoculums and this ensures the successful of the run during the scale-up 
production. From this, we can minimize the lost of money by optimize the yield of 
monoclonal antibody. The production time which is very valuable to the industry 
can become shorter when the yields increase. 
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CHAPTER 2 
 
 
 
 
LITERATURE REVIEW 
 
 
 
 
Animal cells are increasingly grown in bioreactors for the production of 
vaccines and proteins. In such systems the growth and metabolic activity of cells 
depends on many parameters: the chemical composition of the medium, the initial 
physiological state of the cells, the physico-chemical conditions during the culture 
(Griffiths, 1986).In recent years substantial quantitative data have been obtained on 
the influence of the chemical composition of the medium on the kinetics of growth 
and metabolism of several cell lines (Dalili and Ollis1989; and Geaugey et al., 
1989).The influence of operational parameters such as pH, dissolved oxygen, 
osmotic pressure and redox potential have also been reported (Miller et al., 1988 and 
1987).Little has been published , however on the inoculums development. 
 
 
          The handling of a microbial culture, from the time it is transferred from its 
preserved state until it is inoculated into the final location where the microbial 
activity of interest is expressed, is referred to as inoculums development. The 
primary purpose of inoculums development is to provide microbial mass, of 
predictable phenotype, at a specific time, and at a reasonable cost for the productive 
stage of a microbial activity. Until now, inoculums development has been more art 
than science. There remains a need especially at the shake flask or spore-generating 
stages of the process, for time and „it looks good‟ criteria to be replaced with 
biochemical, physiological, or morphological markers as both descriptions of an 
optimum and indicators for optimum timing of inoculums transfer. 
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        It is essential that the culture used to inoculate a fermentation satisfies the 
following criteria: 
1. It must be in healthy, active state thus minimizing the length of the lag phase 
in the subsequent fermentation. 
2. It must be available in sufficiently large volumes to provide an inoculums of 
optimum size. 
3. It must be in a suitable morphological form. 
4. It must be free of contamination. 
5. It must retain its product-forming capabilities. 
 
 
The process adopted to produce an inoculums meeting these criteria is called 
inoculums development. Hockenhull is credited with the quotation “once 
fermentation has been started it can be made worse but not better” (Calam, 1976). 
Where this is an over-statement it does illustrate the importance of inoculums 
development. Much of the variation observed in small-scale laboratory 
fermentations is due to poor inocula being used, thus, it is essential to appreciate that 
the establishment of an inoculums development programme is equally important 
regardless of the scale of the fermentation. Such a programme not only aids 
consistency on a small scale but is invaluable in scaling up the fermentation and 
forms an essential part in progressing a new process (Freshney, 2005). Criteria 
above that apply in microbe fermentation also apply in cell culture.They are equally 
important either to cell culture or microbe fermentation. 
 
 
Figure 1.1 shown the inoculums growth of hybridoma in T flasks. A T flask 
is inoculated with 2X10
5
 cells/ml harvested at the end of 48 hr of propagation. An 
initial fast growth period up to 10X10
5
 cells/ml is observed during the first 50 hr. 
Cell density reaches a maximum at about 60 hr, and then slowly decreases. The first 
24 hr , the cells undergo lag phase after that the log phase begin until the cell density 
reach the maximum at 60 hr , and the cell undergo death phase. This is the growth 
profile of a typical hybridoma cells (Martial et.al, 1990). 
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Figure 2.1: Evolution with time of the viable cell density during the hybridoma T 
flask culture (Martial et.al, 1990). 
 
 
 
 
Several research have been done in inoculums development in hybridoma 
culture, one of it is to check the influence of inoculums age on hybridoma culture.  
Where the inoculums ages that used is 43hr (T1), 52hr (T2), 62hr (T3), and 71hr 
(T4). They investigated in four different spinner flasks inoculated at the same initial 
density of 2x10
5
 cell/ml but with the cells having been propagated in a T flask for 
the above culture durations. In Figure 1.2, they found that T1 and T2 (43 hr and 52 
hr respectively) present two usual growth and death phases of a batch culture, 
without any appreciable initial lag phase. On the contrast, spinners T3 and T4 (62 hr 
and 71 hr respectively) exhibit an initial lag phase lasting as long as 45 hr. The 
viability of the cells, which is initially around 90% for the three first spinners, 
remain high during the whole growth phase and then declines during the death 
phases. For the oldest inoculums, the viability remains around 70% during both the 
lag and growth phases (Martial et.al, 1990).These shows that inoculums age that 
used in stationary phase and death phase will cause the decrease of maximum viable 
cell density, maximum specific growth rate and cell viability (%). 
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Figure 2.2:  Evolution with time of the viable cell density (a) and the viability (b) 
for hybridoma cultures in spinner flasks with different inoculums ages (T1:43 hr; 
T2:52 hr; T3:62 hr; T4:71 hr) (Martial et.al, 1990). 
 
 
 
 
 Figure 1.3 shows the different inoculums age on production of MAb. 
Although the figure shows that when the inoculums age increase, the production of 
MAb decrease in the early stage and no antibodies are produced during lag phase 
especially in T4 but the final antibody levels are essentially the same. Since less 
cells are produced starting from an old inoculums, they conclude that these cells 
have a higher specific production rate of antibodies (Martial et.al, 1990). 
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Figure 2.3: Kinetics of monoclonal antibodies production for hybridoma cultures in 
spinner flasks with different inoculums ages (T1:43 hr; T2:52 hr; T3:62 hr; T4:71 hr) 
(Martial et.al, 1990). 
 
 
 
 
 For the effect of initial density on hybridoma growth and monoclonoal 
antibody production which done by Ozturk and Palson (1990), the range of density 
used is10
2
 to 10
5
 cells/ml. They cultured the murine hybridoma, 167.4G5.3 in 75 
cm
2 
plastic T-flasks with different inoculums density and serum concentration (1.25, 
2.5, 5, and 10% v/v). Figure 1.4, shows the maximum viable cell concentrations and 
maximum IgG antibody concentration for hybridoma culture in Iscove‟s Modified 
Dulbecco‟s Medium (IMDM) supplemented with different serum concentration at 
different initial cell densities. In this figure, it shows that increase the initial cell 
density will increase the maximum viable cells and also maximum antibody 
concentration. 
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Figure 2.4: (A) Maximum cell and (B) maximum IgG concentrations for hybridoma 
cell line 167.4G5.3 in cultures with different serum levels and with different initial 
cell densities (Ozturk and Palsson, 1990). 
 
 
 
 
 Monoclonal antibody concentration increased gradually in all the batches 
following the viable cell count. More antibodies were produced for the cultures with 
higher serum and higher initial cell concentrations. Antibody production continued 
into the decline phase of growth. From the Figure 1.4 (B), a ten-fold increase in 
inoculums size resulted in only a two-fold increase in final antibody concentration. 
From this research, Ozturk and Palson concluded that the maximum viable cell 
antibody concentrations are determined by inoculums sized. The changes in 
antibody concentration were due to changes in cell concentration as the specific 
antibody production rate was not altered (Ozturk and Palsson, 1990). 
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CHAPTER 3 
 
 
 
 
METHODOLOGY 
 
 
 
 
3.1  Basal Medium 
 
 
Around 70 to 80% of 1 L ultrapure water was poured into a 2L beaker. 13.4 
grams of Dulbecco‟s Modified Eagle Medium (D5648, Sigma-Aldrich) was 
dissolved slowly with gentle stirring by magnetic stirrer. The residue in the weighing 
boat was rinsed with little ultrapure water. The solution was stirred for at least 30 
minutes. 3.7 g of sodium bicarbonate (S5761, Sigma-Aldrich) was then added and 
allowed to mix for 10 minutes. 1 g of pluronic F-68 (P1300, Sigma-Aldrich) was also 
added and mixed for further 10 minutes. The volume of the solution was brought to 1 
liter by adding the remainder ultrapure water. The pH was adjusted to 7.2 by using 
0.1N hydrochloric acid. The solution was mixed for another 30 minutes. 17.28µM 
sodium selenite, 4.47µM zinc sulfate and 25.6µM ferric citrate were then added to 
the solution. The solution was mixed and sterile filtered with 0.22µm 
polyethersulfone (PES) membrane filter (F-99505, TPP) into the 1L of Scott bottle 
by using vacuum pump. The filtered medium (basal medium) was kept in the chiller 
(4˚C) for a maximum of 2 months. 
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3.2  Complete Medium 
 
 
To prepare 400 ml complete medium for cell culture, 1.6 ml of fetal bovine 
serum (10091-148, GIBCO), 4 mM L-glutamine (non-animal source, G8540, 
Sigma-Aldrich), and 4 ml of antibiotic-antimycotic (15240-062, GIBCO; 1×) were 
added to a sterile 500ml Scott bottle. Basal medium was then added until the volume 
reach 400 ml. The complete medium was kept in the chiller (4˚C) for a maximum of 
2 weeks. 
 
 
 
 
3.3  Thawed Cell 
 
 
 Cells were thawed by warming a vial of cells in the water bath (35˚C) for a 
maximum of 1 min or until it is partially melt, immediately after removing from the 
-80C freezer. Thawed cells were quickly diluted into a 25 ml warm complete 
medium. The cells were centrifuged (Eppendorf, Germany) at 120g for 5 minutes at 
4˚C.  After centrifugation, the supernatant was discarded and the cells were 
resuspended with 25 ml fresh medium. The cells were then transfered to a T-75 
tissue culture flask and incubated in a humidified CO2 incubator (Shel Lab, United 
State) at 5% CO2 and 37C. 
 
 
 
 
3.4  Cell Count 
 
 
 Before cell count, the tissue culture flask was tapped to dislocate and mix all 
the cells evenly. Hemocyctometer slide and the coverslip were cleaned with the 70% 
ethanol. Kimwipe paper was used to wipe the hemocyctometer slide and cover slip. 
The cell sample was mixed and 20µl sample was transferred to a 0.5 ml centrifuge 
tube. Twenty µl trypan blue dye (for a dilution factor of 2×) was transferred to the 
tube and mix with the sample. Ten µl of this mixture was transferred to the edge of 
the hemocytometer chamber. The cell suspension was drawn under the coverslip by 
capillary action. This was repeated for the other chamber. The hemocytometer was 
